A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia

NCT07396870 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: LY03020
DRUG: Placebo

Sponsor

Luye Pharma Group Ltd.